

editorial

How to increase the quality and visibility of Radiology and Oncology?

Dear friends of Radiology and Oncology. First of all we would like to thank authors and reviewers for their valuable work that significantly contributes to the quality of our journal. Last year we published 58 articles in four issues. The internationality of our journal is evident through the participation of the authors from many European and other countries throughout the world. Furthermore, in 2015 our Impact factor increased to 1.912. We regret, but according to the limited place, we were unable to accept many manuscripts for publication. Currently we have been able to publish only part of submissions. The rejecting rate was about 78% (58/262). Thus, many otherwise worthwhile papers were not accepted relative to their publication priority assigned by the reviewers and editors.

The published articles are well cited. Many authors from the United States and from China quoted papers from Radiology and Oncology. Furthermore, they were quoted also in some prestigious journals, such as Nature Reviews Cancer. This trend we would like to continue in the future.

Our journal is general in the fields of oncology, radiology and nuclear medicine. We publish works from basic research to clinical studies. In relation to that we decided this year to devote part of the first issue to a theme of biomedical applications of electroporation. Our guest editors, Prof. Richard Heller from USA and Prof. Maja Čemažar from Slovenia have prepared several interesting manuscripts that are published in this issue of Radiology and Oncology. The results were in major part presented at the 1st World congress on electroporation that was held in Portorož in September 2015.

Our intended next step in development of Radiology and Oncology is to apply for the MEDLINE. They adhere to specific requirements that journals have to follow. Among them are ethical issues that we have to comply with. Therefore we require that all clinical and animal data have clearance of the respectful bodies. We will also start to enforce that the prospective clinical studies - beside ethical consideration - are registered either in European or American clinical studies repositories. We would like to inform the authors and also the reviewers to be very strict in this respect.

In the end we would like to thank you again for the support of our efforts for continuous development of Radiology and Oncology.

With best regards,

Prof. Gregor Serša, Ph.D.
Editor in Chief

Assoc. Prof. Viljem Kovač, M.D., Ph.D.
Executive Editor